Last updated 2026-08-24
- Raised $20M Undisclosed Round led by Premas Biotech Pvt. Ltd., Nov 2021
- Raised Undisclosed Round led by Premas Biotech, Mar 2021
Total raised
$20.0M
Stage
—
Founded
2021
Headcount
—
HQ
Jerusalem, Israel
Sector
Biomed
About
Oravax is developing breakthrough technologies for the delivery of oral vaccines. The company's technology seamlessly integrates a novel approach to vaccines from Premas Biotech based on their D-Crypt™ technology with an oral delivery platform from Oramed Pharmaceuticals based on their proprietary POD™ delivery technology. Oravax is developing an oral COVID-19 vaccine that targets three SARS CoV-2 virus surface proteins, including proteins less susceptible to mutation, making it a candidate for protection against emerging mutated viruses.
Funding history · 2 rounds · $20.0M total
2021-11
Undisclosed Round
$20.0M
★ Premas Biotech Pvt. Ltd.★ Genomma Lab Internacional★ Oramed Pharmaceuticals Inc.★ Tan Thanh Holdings Investment Joint Stock Company
2021-03
Undisclosed Round
Undisclosed
★ Premas Biotech★ MyMD Pharmaceuticals★ certain other shareholders★ Oramed Pharmaceuticals Inc.
Q&A
- What is Oravax Medical Ltd.'s primary business focus?
- Oravax Medical Ltd. is a Biomed company dedicated to developing oral vaccine technologies, specifically an oral COVID-19 vaccine.
- When was Oravax Medical Ltd. founded?
- Oravax Medical Ltd. was founded in 2021.
- How much funding has Oravax Medical Ltd. raised to date?
- Oravax Medical Ltd. has raised a total of $20,000,000 in funding.
- Which companies participated in Oravax Medical Ltd.'s Undisclosed Round in November 2021?
- Ltd. and Genomma Lab Internacional.
- What is the relationship between Oravax Medical Ltd. and Oramed Pharmaceuticals Inc.?
- Oramed Pharmaceuticals Inc. is the largest shareholder and majority owner of Oravax Medical Ltd.
- What is Nadav Kidron's role at Oravax Medical Ltd.?
- Nadav Kidron serves as the Chairman of Oravax Medical Ltd., a position he has held since March 2021. He is also the CEO of Oramed.
- What type of vaccine technology does Oravax Medical Ltd. utilize for its COVID-19 candidate?
- Oravax Medical Ltd.'s COVID-19 vaccine candidate is a virus-like particle (VLP) triple antigen vaccine designed to target three structural proteins, aiming for broader protection against emerging mutations.
- Where is Oravax Medical Ltd. headquartered?
- Oravax Medical Ltd. is headquartered in Jerusalem, Israel.
Team · 1
Nadav Kidron
Chairman
Sectors & technology
Primary sector
Biomed
Target customers
Business model
B2B
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | ora-vax.com |
|---|
Identifiers & details
| Founded | 2021 |
|---|
Radar intelligence
Web history (Wayback)
| Domain | ora-vax.com |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 516499654 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2021-11-23 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | yes |
| Last annual report | 2024 |
| Active charges / liens | 0 |
| Registry events | 1 — violation (1) |
| Registered address | ממילא 20 ירושלים |
Recent registry events
| Date | Event |
|---|---|
| 2026-06-25 | עדכון הפרה |